Research Article
Intermittent Chemotherapy and Erlotinib for Nonsmokers or Light Smokers with Advanced Adenocarcinoma of the Lung: A Phase II Clinical Trial
Table 2
Response to treatment, time to progression, and survival in relation to EGFR mutations.
| | | EGFR mutations | | | | Positive | Negative | Unknown | All |
| | Response to treatment | CR | 4 | — | 1 | 5 | | PR | 4 | 2 | 3 | 9 | | SD | — | 6 | 2 | 8 | | Progression | — | 2 | — | 2 | | Time to progression (months) | Median (95% CI) | 21.5 (14.8–27.2) | 5.0 (0.9–9.1) | 5.0 (3.9–4.1) | 13.4 (5.4–20.6) | | Survival (months) | Median (95% CI) | 24.2 | 7.0 (0.1–13.9) | 11.0 | 23.0 (10.9–35.2) |
|
|
